This article will address the issue of Mubritinib, which has become very relevant in recent times. Mubritinib is a topic that impacts a large number of people in different areas of life, whether professional, personal, social or cultural. Throughout this article, different aspects related to Mubritinib will be explored, from its origin and evolution to its possible future implications. Different perspectives and opinions on the matter will also be analyzed, with the aim of offering a complete and enriching vision of this topic of great interest to today's society.
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C25H23F3N4O2 |
Molar mass | 468.480 g·mol−1 |
3D model (JSmol) | |
| |
|
Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.